Module contents

Module home
Module introduction
Module information
About the author

Learning notes

Pre-module test

 

Section 1: Setting the scene – what is polypharmacy?

(1.1) Section 1: Setting the scene – what is polypharmacy?

(1.2) What is polypharmacy used for?

(1.3) Reasoning behind polypharmacy

(1.3) Interactive exercise: why does polypharmacy occur?

(1.4) Rational and creative polypharmacy

(1.5) Differences between rational and creative polypharmacy

(1.6) Explanations for polypharmacy

(1.7) And finally...

(1.8) Section 1: Recap

(1.9) Section 1: Summary

 

Section 2: Polypharmacy in schizophrenia

(2.1) Section 2: Polypharmacy in schizophrenia

(2.2) Clinical vignette: Alan

(2.3) Suggested answers

(2.4) Prevalence

(2.5) Managing treatment-resistant schizophrenia

(2.6) Table 3: Clinical and research perspective on combining different groups of psychotropics with antipsychotics

(2.7) Predictors of polypharmacy in schizophrenia

(2.8) A word of caution

(2.9) Clinical guidelines in the management of schizophrenia

(2.10) Conclusion

(2.11) Reflection

(2.12) Section 2: Recap

(2.13) Section 2: Summary

 

Section 3: Polypharmacy in bipolar affective disorder

(3.1) Section 3: Polypharmacy in bipolar affective disorder

(3.2) Clinical vignette: Mr Broadbent

(3.3) Suggested answers

(3.4) Prevalence

(3.5) Causes for polypharmacy in bipolar effective disorder: severity of illness

(3.6) Causes for polypharmacy in bipolar effective disorder: difficulty in establishing diagnosis

(3.7) Current practice

(3.8) Current practice

(3.9) Table 4: Common adverse effects from polypharmacy in affective disorder

(3.10) Unity in diversity

(3.11) Adding antidepressants

(3.12) Combining mood stabilisers

(3.13) Role of antipsychotics

(3.14) Clinical guidelines in the management of bipolar affective disorder

(3.15) Reflection

(3.16) Section 3: Recap

(3.17) Section 3: Summary

 

Section 4: Polypharmacy in depression

(4.1) Section 4: Polypharmacy in depression

(4.2) Clinical vignette: Mrs Taylor

(4.3) The current situation

(4.4) MAOIs

(4.5) Augmentation strategies

(4.6) Table 5: Should we combine or switch medications?

(4.7) Augmentation strategies (cont..)

(4.8) Combining atypical antipsychotics with antidepressants

(4.9) Clinical guidelines in the management of depression: NICE

(4.10) Clinical guidelines in the management of depression: BAP

(4.11) Suggestions for good practice

(4.12) Section 4: Recap

(4.13) Section 4: Summary

 

Section 5: Polypharmacy in anxiety disorders

(5.1) Section 5: Polypharmacy in areas anxiety disorder

(5.2) Clinical vignette

(5.3) Anxiety disorders

(5.4) Clinical guidelines for anxiety disorders

(5.5) Reflection

(5.6) Section 5: Recap

(5.7) Section 5: Summary

 

Section 6: Surviving the scare

(6.1) Section 6: Surviving the scare

(6.2) Polytherapy against polypharmacy

(6.3) One size does not fit all

(6.4) Interactive exercise: questions to ask before prescribing

(6.5) Before initiating polypharmacy

(6.6) On polypharmacy

(6.7) After polypharmacy

(6.8) Final words

(6.9) Section 6: Recap

(6.10) Section 6: Summary

 

Module summary

Module test

Send feedback

 

Useful resources

Take-home notes

References

Further reading

Useful websites

© 2022 Royal College of Psychiatrists